Daniela Cipolletta

Company: Seismic Therapeutic

Job title: Senior Director of Immunology

Bio:

Daniela Cipolletta is Senior Director of Immunology at Seismic Therapeutic, where she leads the generation of novel therapies for autoimmune diseases. With over 20 years of experience in immunology, she has held positions at Novartis, Amgen, and Tempero (a GSK company), focusing on immune modulation across various disease areas. Dr. Cipolletta earned her Ph.D. in Immunology from the European School of Molecular Medicine and completed postdoctoral training at Harvard Medical School, where she researched tissue-resident regulatory T cells 

Seminars:

Reprogramming Autoimmunity Using S-4321, a PD-1:FcγRIIb Dual-Cell Bidirectional Antibody 11:30 am

S-4321is a novel dual-cell bidirectional PD-1:FcγRIIb antibody that activates the inhibitory PD-1 receptor on T cells while selectively engaging FcγRIIb on antigen-presenting cells. This dual action helps restore immune balance in diseases driven by dysregulated cell-mediated immunity  Through its Fc domain, S-4321 selectively engages FcγRIIb, preventing the depletion of PD-1-expressing T cells (including regulatory T…Read more

Unlocking New Immune Pathways: Discussing B-Cell Depletion & Beyond in Autoimmune Therapy 9:10 am

Discussing the latest B-cell depletion data across diseases to assess effectiveness and potential for expansion into dermatological diseases such as psoriasis Evaluating if B-cell depletion remains the most promising approach and exploring the potential to move beyond B-cell targeting (including, Mast Cells, T-cells, Macrophages, Myeloid Cells and more) Exploring immune cell depletion across disease indications…Read more

day: Day Two

Evaluating Bi-Specific Antibody & Cell Engager Targets, Safety & Efficacy to Uncover Their Commercial Potential 12:10 pm

Exploring emerging classes of cell engager and bispecific therapies, evaluating target populations, including macrophages, to identify applications in wider autoimmune diseases Comparing toxicity concerns for a broad population or efficacy in more targeted populations to evaluate the safety of engager and antibody applications Evaluating the safety and efficacy of bispecific antibody & cell engagers, in…Read more

day: Day Two

Uncovering Modality, Precision Targeting & Global Partnership Synergies to Advance Autoimmune Combination Therapy Innovations 3:00 pm

Discussing optimal modality combinations, considering checkpoint agonism, bispecific, monoclonal and fixed dose oral approaches, to safety tailor combinations for complex autoimmune diseases, including IBD and RA Evaluating the balance of known and novel targets to align with safety profiles and unmet patient needs Exploring partnership opportunities with the rapidly expanding bispecific market in Asia and…Read more

day: Day Two